Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. (HALO) generates news that spans drug delivery technology, clinical applications, strategic collaborations and corporate finance. As a biopharmaceutical company focused on subcutaneous administration of biologics, Halozyme’s announcements often highlight how its ENHANZE and Hypercon platforms are being integrated into partner therapies and new indications.
News items frequently cover collaboration and license agreements with global pharmaceutical and biotechnology companies. Examples include agreements with Takeda to use ENHANZE with vedolizumab and with Merus to develop a subcutaneous formulation of petosemtamab. These stories typically describe upfront payments, potential milestones and royalty structures, as well as the therapeutic areas targeted by ENHANZE-enabled products.
Another major category of HALO news involves regulatory milestones achieved by partner products that incorporate Halozyme technologies. Recent press releases describe U.S. Food and Drug Administration approvals for DARZALEX Faspro and RYBREVANT FASPRO, both co-formulated with ENHANZE, in multiple myeloma and EGFR-mutated non-small cell lung cancer. Such updates provide insight into how Halozyme’s platforms translate into commercial products and expanded indications.
Halozyme also issues updates on intellectual property and legal matters, including patent enforcement actions related to its MDASE portfolio and court decisions affecting subcutaneous formulations of other companies’ drugs. In addition, investors can follow corporate developments such as acquisitions, including the purchase of Elektrofi and its Hypercon technology, board appointments, executive transitions and participation in healthcare conferences.
For investors and industry observers, the HALO news feed offers a way to track the evolution of Halozyme’s partnership base, the progress of ENHANZE- and Hypercon-enabled products, and key events that may influence the company’s royalty outlook and strategic direction.
Halozyme Therapeutics (NASDAQ: HALO) will be represented by Elaine Sun, CFO, in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 3:30 p.m. ET. The event will be accessible via an audio link on the company's website, with a recording available for six months. Halozyme focuses on biopharmaceuticals, utilizing its ENHANZE technology to improve treatment delivery, impacting over 500,000 patients through partnerships with major pharmaceuticals.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will host its second quarter 2021 conference call on August 9 at 4:30 p.m. ET. The call will be led by CEO Dr. Helen Torley and will follow the release of financial results for the quarter ending June 30, 2021. Investors can register via a provided link, and the event will be webcast live on Halozyme's corporate site. Halozyme's technology aims to enhance patient experiences, with its solutions impacting over 500,000 patients globally through multiple commercialized products.
Halozyme Therapeutics (NASDAQ: HALO) announced that Janssen Biotech has received FDA approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with pomalidomide and dexamethasone for treating adults with multiple myeloma after prior therapy. This marks the sixth indication for DARZALEX FASPRO® in multiple myeloma treatment. The approval is backed by positive results from the Phase 3 APOLLO study, highlighting improved progression-free survival. Halozyme's ENHANZE® drug delivery technology underpins this therapy, enhancing patient treatment experiences through subcutaneous delivery.
Halozyme Therapeutics (NASDAQ: HALO) announced that the European Commission granted Janssen Pharmaceutical marketing authorizations for the subcutaneous formulation of daratumumab, known as DARZALEX® SC. This includes an authorization for treating adults with newly diagnosed systemic light-chain amyloidosis (first approved therapy for AL amyloidosis in Europe) and for adults with multiple myeloma who are lenalidomide refractory. These approvals enhance treatment options for specific patient groups in Europe, furthering Halozyme's commitment to improving patient outcomes.
ViiV Healthcare and Halozyme Therapeutics have entered a global collaboration that grants ViiV exclusive access to Halozyme's ENHANZE® drug delivery technology for HIV treatments. ViiV will pay $40 million upfront, with potential milestone payments totaling up to $175 million per target. This partnership aims to enhance the development of long-acting HIV therapies, reducing the frequency of medication. The PH20 enzyme allows for efficient large-volume subcutaneous injections, potentially addressing treatment challenges for patients and improving their experience.
ViiV Healthcare and Halozyme Therapeutics have formed a collaboration to utilize Halozyme's ENHANZE® drug delivery technology for HIV treatment and prevention. ViiV will pay Halozyme $40 million upfront, with potential future payments totaling $175 million based on development milestones. This partnership aims to develop ultra-long acting HIV medicines, reducing the treatment burden for patients. Halozyme's enzyme technology enables rapid delivery of large volumes of medication, potentially extending dosing intervals beyond current standards. The collaboration could lead to innovative options in HIV therapies.
Halozyme Therapeutics (NASDAQ: HALO) announced presentations of collaborative studies utilizing ENHANZE® technology at the 2021 ASCO Annual Meeting from June 4-8. Key studies included Phase 3 results for AL amyloidosis treatment and preliminary analyses of nivolumab. Highlights also featured cost analysis for a fixed-dose combination treatment for HER2-positive breast cancer. Halozyme's ENHANZE® technology aims to enhance patient treatment experiences, and the company has licensed this technology to major pharmaceutical firms. The press release emphasizes ongoing development and collaboration, impacting potential revenue through milestones and royalties.
Halozyme Therapeutics (NASDAQ: HALO) announced its participation in two upcoming virtual investor conferences. The first is the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, featuring Dr. Helen Torley at 11:20 a.m. ET. The second is the JMP Securities Life Sciences Conference on June 17, 2021, with Elaine Sun at 3:00 p.m. ET. Live webcasts will be available on their website, along with archived recordings for a month after each event.
Halozyme Therapeutics (NASDAQ: HALO) announced that Janssen received positive opinions from the EMA's CHMP for expanding DARZALEX® (daratumumab) subcutaneous formulation to treat AL amyloidosis and relapsed multiple myeloma. The first opinion supports the use of DARZALEX® with cyclophosphamide, bortezomib, and dexamethasone for newly diagnosed AL amyloidosis patients. The second opinion recommends its use with pomalidomide and dexamethasone for specific multiple myeloma patients. These recommendations will be reviewed by the European Commission for final approval.
Halozyme Therapeutics (NASDAQ: HALO) reported strong Q1 2021 results with revenues of $89 million, a 250% increase from $25.4 million in Q1 2020. Key drivers included $30 million in milestone revenues from Janssen and Bristol Myers Squibb, and a 119% rise in royalty revenue from subcutaneous DARZALEX®. Operating income reached $50.7 million compared to a loss of $3.2 million a year earlier. The company expects 2021 revenues between $375 million and $395 million, reflecting 40%-48% growth. Cash and equivalents totaled $764.3 million at quarter-end.
FAQ
What is the current stock price of Halozyme Thrp (HALO)?
What is the market cap of Halozyme Thrp (HALO)?
